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The association of Taq 1 and Fok 1 restriction fragment length polymorphisms of the vitamin D receptor with occurrence and
outcome of malignant melanoma (MM), as predicted by tumour (Breslow) thickness, has been reported previously. We now report a
novel adenine–guanine substitution  1012bp relative to the exon 1a transcription start site (A-1012G), found following screening
by single-stranded conformational polymorphism of this promoter region. There was a total of 191 MM cases , which were stratified
according to conventional Breslow thickness groups, cases being randomly selected from each group to form a distribution
corresponding to the known distribution of Breslow thickness in our area, and this population (n¼176) was compared to 80
controls. The A allele was over-represented in MM patients and, with GG as reference, odds ratio (OR) for AG was 2.5, 95%
confidence interval (CI) 1.1–5.7, (P¼0.03) and AA 3.3, CI 1.4–8.1, (P¼0.007). The outcome was known in 171 of 191 patients and
the A allele was related to the development of metastasis, the Kaplan–Meier estimates of the probability of metastasis at 5 years
being: GG 0%; AG 9%, CI 4–16%; AA 21%, CI 12–36%; (P¼0.008), and to thicker Breslow thickness groups (P¼0.04). The effect
on metastasis was independent of tumour thickness and A-1012G may have predictive potential, additional to Breslow thickness.
Neither the Fok 1 nor Taq 1 variants (f and t) were significantly related to the development of metastasis, although there was a strong
relationship of fftt with the thickest Breslow thickness group (P¼0.005). There was an interaction between the A-1012G and Fok 1
polymorphisms (P¼0.025) and the Fok 1 variant enhanced the effect of the A allele of the A-1012G polymorphism on metastasis,
the probability of metastasis for AAff at 5 years follow-up being 57%, CI 24–92%.
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The polymorphisms of the vitamin D receptor (VDR), reported in
the literature, comprise a cluster of tightly linked polymorphisms
at the 30-end and two polymorphisms at the 50-end of the gene. The
30 polymorphisms are Apa 1 (Faraco et al, 1989) and Bsm 1
(Morrison et al, 1992) in intron 8, Taq 1(Morrison et al, 1992) in a
silent site in exon 9 and a length polymorphism of a polyadenyl
(polyA) microsatellite in the 30-untranslated region (Ingles et al,
1997b), classified into long (L) and short (S) variants (L
demonstrates linkage disequilibrium with b, a, T). The 50
polymorphisms are Fok 1(Saijo et al, 1991) situated in exon 2,
10 base pairs upstream from an ATG translation start point, and a
recently described polymorphism in the promoter region, situated
at  3731bp relative to the exon 1a transcription start site (Arai
et al, 2001) within a binding element of Cdx-2, which is a caudal-
related homeodomain transcription factor. The 30 region poly-
morphisms do not affect VDR protein structure, while Fok 1 (C–T
transition) alters an ACG codon resulting in a further upstream
start codon and a three amino-acid extended protein (Saijo et al,
1991). Both the 30 and Fok 1 polymorphisms have been reported to
be functional in terms of VDR transactivation (Whitfield et al,
2000). Cdx-2 is important during the development of the intestine
and in adults it has been shown to regulate VDR expression in the
small intestine (Yamamoto et al, 1999). The expression of Cdx-2
has also been found in other tissues such as the brain and prostate.
Polymorphism at the Cdx-2-binding site significantly alters the
transcriptional activity of the VDR promoter region (Arai et al,
2001).
Since 1996, there have been many reports of associations of
polymorphisms of the VDR with systemic carcinomas. The 30
polymorphisms have been reported to be associated with the
occurrence and outcome, as assessed by metastasis or presence of
adverse prognostic markers, of prostatic cancer (Taylor et al, 1996;
Ingles et al, 1997c; Ingles et al, 1998; Ma et al, 1998; Habuchi et al,
2000; Hamasaki et al, 2001; Medeiros et al, 2002), breast cancer
(Curran et al, 1999; Lundin et al, 1999; Ingles et al, 2000;
Bretherton-Watt et al, 2001; Cui et al, 2001; Schondorf et al, 2003)
and renal cancer (Ikuyama et al, 2002). Fok 1 polymorphisms have
been reported to be associated with the outcome of prostate cancer
(Hamasaki et al, 2002) and occurrence of breast (Ingles et al,
1997a) and colon (Wong et al, 2003) cancers. However, other
studies have failed to find an association with prostate cancer
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s(Jenkins et al, 1997; Dunning et al, 1999; Luscombe et al, 2001) or
breast cancer (Correa-Cerro et al, 1999; Furuya et al, 1999;
Watanabe et al, 1999; Blazer et al, 2000; Chokkalingam et al, 2001),
but many of these (Jenkins et al, 1997; Correa-Cerro et al, 1999;
Furuya et al, 1999; Watanabe et al, 1999; Blazer et al, 2000) were
relatively limited studies of approximately 100 or less cases. The
Cdx-2 polymorphism has been linked with increased risk in cancer
of the prostate (Bodiwala et al, 2004).
We have previously reported an association with the occurrence
and, particularly, the outcome of malignant melanoma (MM), as
assessed by Breslow tumour thickness and polymorphisms at the
Fok 1 and Taq 1 restriction sites (ttff) (Hutchinson et al, 2000). We
now describe a new polymorphism in the promoter region
upstream of the exon 1a transcription start site, A-1012G. We
report investigations into the relationship of the A-1012G and A-
1012G/Taq 1 and A-1012G/Fok 1 genotype combinations with the
occurrence and outcome of MM, in terms of the development of
metastasis and as predicted by Breslow thickness and compare the
strength of the A-1012G polymorphism with the corresponding
relationships of Taq 1 and Fok 1.
MATERIALS AND METHODS
Single-stranded conformational polymorphism (SSCP)
analysis
All oligonucleotide primers used for PCR are shown in Table 1. A
B2500bp region from 120bp upstream of exon 1e to 70bp
downstream of exon 1d including exon 1a was amplified by PCR in
10 overlapping amplicons of B350bp (primers 1A/Dp1-10) for 35
cycles with an annealing temperature of 601C in PCR buffer (45mM
Tris-HCl (pH 8.8), 11mM (NH4)2SO4, 4.5mM MgCl2, 110mgml
 1
BSA, 6.7mM b-mercaptoethanol 4.4mM EDTA (pH 8.0), 200mM
dNTPs). Each amplicon was screened for variation by SSCP in 36
control samples. A measure of 3ml PCR product was added to 9ml
denaturing loading buffer (95% formamide, 0.25% bromophenol
blue, 0.25% xylene cyanol, 10mM sodium hydroxide) and heated to
951C for 3min, chilled on ice and loaded onto a 0.6–0.8 MDE
(BioWhittaker, 50620) gel, depending on amplicon size, in 0.6%
TBE buffer and run at 500V for 30min followed by 270–350V
overnight, depending on amplicon size. Where variation was
found, variant bands were reamplified from the gel and sequenced
by Big Dye sequencing on an ABI prism 377 sequencer.
The possible effects of sequence variation on promoter activity
were determined by the analysis of potential transcription factor-
binding sites within variable regions using the TESS database
(Schug and Overton, 1997).
Genotype screening
To screen for the promoter polymorphism in patients and
controls, a 150bp region around the polymorphism was amplified
using primer pair SNP1 (Table 1). PCR cycling was carried out
with a 551C annealing temperature for three cycles followed by
651C for 37 cycles. The forward primer was adjacent to the
polymorphism and mutated the sequence to introduce an EcoRV
restriction site in the A allele but not in the G allele such that in
subsequent EcoRV digestion (371C, 20h), followed by agarose-gel
electrophoresis, the A allele was restricted and the G allele
remained uncut. Fok 1 and Taq 1 were amplified with the
appropriate primers (Hutchinson et al, 2000) for 35 cycles with an
annealing temperature of 601C. PCR products were then digested
with Fok 1 (371C, 20h) or Taq 1 (651C, 20h). The Fok 1 F and
Taq 1 T alleles were refractory to digestion, while the f and t alleles
were restricted.
MM studies
Patients with a diagnosis of MM who attended the Pigmented
Lesion Clinic between 1995 and 1997 were recruited. Patients with
lentigo maligna melanoma were not included. It was attempted to
recruit all patients, but this was not always possible in busy clinics.
Documented data were age at presentation, gender, skin type based
on the Fitzpatrick classification (Fitzpatrick, 1988), eye colour, hair
colour at age 21 years, tumour site and Breslow group and
presence of metastases on follow-up. Breslow thickness (defined as
the vertical thickness of the tumour from the granular layer of the
epidermis to the deepest part of the melanoma) was determined by
specialist pathologists. On the basis of Breslow thickness, patients
were divided into five conventional Breslow thickness groups (0–
4); in situ, o0.75mm, 0.75–1.49mm, 1.5–3.49mm and X3.5mm
(Mackie et al, 1985). For the occurrence studies, a subsample of
patients were stratified according to Breslow thickness group to
conform with frequencies within groups according to the reported
distribution in the Leicestershire area (n¼738) (Osborne and
Hutchinson, 2001). Controls consisted of UK Caucasian patients
not known to have cancer. This study was approved by the local
Ethics Committee and written informed consent was given by the
patients.
Table 1 Oligonucleotide sequences used as PCR primers
Primer pair Forward primer Reverse primer Amplicon position (bp)
1A/Dp1 CTGATGACGGCATGTGCT CAGCCTTTGTTGGAGGAGAG  2119 to  1755
1A/Dp2 CAGTGGGATGTGCAGAGAGA GCTAGCGGTGATTCTTGTGG  1979 to  1529
1A/Dp3 AGATGTCAGGCCAGTCAAGC GGTATCATGGCAACTTTCTGG  1676 to  1329
1A/Dp4 ATGGTCCATTCCCAAGTTCA CAGAGGGACAAGGTGAAAGG  1411 to  1051
1A/Dp5 AGCAGATTTGCTGGGCTCTA TGCTTCCCTTGACTGTGTGA  1163 to  818
1A/Dp6 TCCCACTGCACAGTGAGTTC AAGTGGAAACCGGAGTTGC  914 to  554
1A/Dp7 GATATCGGGTGGGAGCAAT TGGGACAGAGTTGTCGATGA  594 to  232
1A/Dp8 ACAGGCTGAAGCGGGTATC CCGAGTCCCTATCCTGAGAC  281 to +126
1A/Dp9 GCAAGAGAGGACTGGACCTG GCGGAGCATTTCTCCTAAGC  94 to +334
1A/Dp10 TCTCAGCGGTAAACTTGGCTA AGACCCAACTCCACCATCAC +186 to +535
SNP1 CCTCCTCTGTAAGAGGCGAATAGCGAT GGACAGGTGAAAAAGATGGGGTTC  1039 to  861
Fok 1 CTGGCACTGACTCTGGCTCT TGCTTCTTCTCCCTCCCTTT  48 to +199
a
Taq 1 CAGAGCATGGACAGGGAGCAAG CGGCAGCGGATGTACGTCTGCAG  260 to +338
b
PCR¼polymerase chain reaction; bp¼base pair. All amplicon positions are relative to the exon 1a start site except
arelative to the start of exon 2 and
brelative to the start of
exon 9.
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Occurrence and Breslow thickness data were analysed by
contingency tables (Unistat Statistical Package, version 5.0,
Unistat, UK) and logistic regression (Stata software package,
version 7.0, Stata Corporation, Texas, USA). Metastatic data were
analysed using the Kaplan–Meier product limit estimator (Uni-
stat), with the log-rank comparison statistic, and by the Cox’s
proportional-hazard model (Stata). Interactions were assessed by
the Cox’s likelihood-ratio test (Stata).
RESULTS
Promoter screening
Single-stranded conformational polymorphism revealed variation
in the 1A/Dp5 region ( 1163 to  818bp). Sequencing of the
variant bands revealed an A–G polymorphism, at  1012bp
relative to the exon 1a transcription start site (Figure 1). Therefore,
the sequence in the region was either:  1020 ATAGCAATATCTTC
or  1020 ATAGCAATGTCTTC.
Analysis with the TESS database revealed a strong GATA-3 core-
binding site at this locus in the A allele (given in italics above),
which was not present on analysis of the G allele.
MM studies
The percentages of MM in each Breslow thickness group
presenting in Leicestershire in the past 10 years are as follows:
in situ, 13.8%; o0.75mm, 26.6%; 0.75–1.49mm, 21.5%; 1.5–
3.49mm, 21.0% and X3.5mm, 17.1%. A total of 191 patients were
recruited. The numbers of patients randomly chosen for allocation
to the respective thickness groups from the 191 patients were 24
(13.6%), 49 (27.8%), 35 (19.9%), 38 (21.6%) and 30 (17.0%). The
total number of MM patients for the occurrence study was
therefore 176 (mean age 54.3 years, 110 females) and there were 80
controls (mean age 56.2 years, 40 females). Age or sex did not have
a statistically significant relationship with VDR promoter genotype
in either controls or MM patients. In the metastatic outcome part
of the study, there was a total of 171 of 191 patients in whom the
outcome was known.
Table 2 shows allele and genotype frequencies in controls and
MM patients. Genotype frequencies conformed to the Hardy–
Weinberg equilibrium in both subject groups. The A allele was
over-represented in the MM patients (P¼0.03). Similarly, AA
genotype was more and GG less frequent in MM patients
(P¼0.03). Correcting for age and sex and with GG as reference,
odds ratio (OR) for AG was 2.5, 95% confidence interval (CI) 1.1–
5.7 (P¼0.03) and AA 3.3, CI 1.4–8.1, (P¼0.007).
The mean time to metastasis was 31 months (range 1–171
months) (n¼19) and mean follow-up time in patients not
developing metastasis was 75 months (3–255 months) (n¼152).
Figure 2 shows Kaplan–Meier curves for metastasis-free times for
Figure 1 Sequencing traces of the region around the polymorphism, the variable base is marked by an arrow.
Table 2 Allele and genotype frequencies of A-1012G in MM patients
and controls
Alleles Genotypes
A G AA AG GG
Controls 86 (54%) 74 (46%) 22 (27%) 42 (52%) 16 (20%)
MM patients 244 (64%) 140 (36%) 66 (38%) 92 (53%) 16 (9%)
P¼0.03 P¼0.03
MM¼malignant melanoma.
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The Kaplan–Meier estimates of the probability of metastasis at 5
years follow-up were: GG 0%; AG 9%, CI 4–16%; AA 21%, CI 12–
36%. The results of Cox’s proportional-hazard regression analysis
are shown in Table 3. As there were no metastases with genotype
GG, hazard ratios (HR) for AA and AG compared with GG were
not reliable and therefore AA vs AG/GG are shown, confirming a
significantly worse prognosis for AA. Inclusion of the covariates,
age at onset, male gender, skin type, eye and hair colour and
lesional site made no significant impact on this (results not
shown).
Conversely, the A-1012G polymorphism was not strongly
associated with Breslow thickness (n¼191), although for Breslow
thickness groups two, three and four combined vs groups zero and
one combined (X1.5mm vs o1.5mm depth); OR for AA vs other
genotypes was 1.9 (CI 1.0–3.6, P¼0.04). The relationship of
promoter polymorphism and metastasis was reinvestigated
correcting for Breslow thickness, when HR for AA vs any other
genotype was 2.7, which was very similar to the uncorrected value
of 2.9, suggesting that the effect of the polymorphism on metastasis
was largely independent of depth of invasion. Table 4 shows the
proportion of patients in each promoter genotype/Breslow
thickness group who developed metastasis. The highest proportion
occurred in patients who had both AA genotype and the thickest
tumours (Breslow thickness X3.5mm, group 4). However, some
patients with thin tumours developed metastasis but only in the
presence of the AA genotype.
The Taq 1 homozygote variant (tt) was associated with Breslow
thickness groups three and four combined (Breslow thickness
X1.5mm) when corrected for age at presentation, sex, skin type
eye and hair colour and site of MM (OR 3.1 CI 1.2–8.3, P¼0.02)
but the Fok 1 homozygote variant (ff) was not (OR 1.4, CI 0.6–3.5,
P¼0.5). The fftt genotype combination was strongly associated
with the thickest Breslow thickness group, group 4 (OR 24, CI 3–
225, P¼0.005). Similarly, tt, ff and ttff were not significantly
associated with poorer prognosis in terms of metastasis (Table 3).
There was some correlation between A-1012G with Fok 1
polymorphisms (F and A), Spearman’s rank correlation 0.15
(P¼0.01) but not with Taq 1 (P¼0.5). There was a statistically
significant interaction of the A-1012G with Fok 1 polymorphisms
(P¼0.025) but not with Taq 1. Considering A-1012G/Fok 1 and A-
1012G/Taq 1 genotype combinations (Figure 3), the Kaplan–Meier
estimates of the probability of metastasis at 5 years follow-up were
AAff 57%, CI 24–92%; AAFF 18%, CI 8–38%; GGff 0%; GGFF 0%
and all other genotypes 6%, CI 3–13%, (P¼0.001). On Cox’s
proportional-hazard model regression (Table 3), there was a strong
effect of AAff, which was associated with a greater metastatic rate
than AAFF/Ff (HR 4.7, P¼0.03) when corrected for the other
covariates. This difference was greater than the corresponding
comparison of ff vs FF/Ff (HR 1.3, P¼0.6).
DISCUSSION
This newly described polymorphism of the 1a promoter, A-1012G,
has been found to be related to occurrence of MM (Table 2), the A
allele being over-represented in the MM population. When
investigating the effect of a variable on occurrence of a
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Figure 2 Kaplan–Meier estimates of the probability of metastasis for
A-1012G genotypes.
Table 3 Results of Cox’s proportional-hazard regression analysis
(univariate) of metastatic rate on A-1012G, Fok 1 and Taq 1 genotypes,
and on A-1012G genotype combinations with Fok 1 and Taq 1
Polymorphisms Genotype Number HR 95% CI Significance
A-1012G GG/AG 110 1
AA 59 2.9 1.1–7.5 P¼0.03
Fok FF/Ff 140 1
Ff 30 1.3 0.4–4.1 P¼0.6
Taq TT/Tt 143 1
Tt 26 1.5 0.5–4.6 P¼0.5
Fok/Taq Other genotypes 165 1
ff/tt 4 2.2 0.3–16.3 P¼0.5
A-1012G/Taq Other genotypes 130 1
AATT 27 2.5 0.9–7.4 P¼0.1
Aatt 11 3.1 0.8–11.2 P¼0.1
A-1012G/Fok Other genotypes 130 1
AAFF 30 4.3 1.5–12.4 P¼0.006
AAff 9 8.6 2.5–29.6 P¼0.001
AAFF/Ff 50 1
AAff 9 4.7 1.2–18.6 P¼0.03
HR¼hazard ratio; CI¼95% confidence interval for hazard ratio estimate. Bold
numerals represent statistically significant results.
Table 4 Proportion of patients developing metastases in relation to
Breslow group of the melanoma and A-1012G genotype
Breslow thickness group
In situ o0.75mm 0.75–1.49mm 1.5–3.49mm X3.5mm
GG 0% (0/3) 0% (0/5) 0% (0/3) 0% (0/4) 0% (0/2)
AG 0% (0/13) 0% (0/30) 0% (0/17) 17% (3/18) 27% (4/15)
AA 0% (0/7) 8% (1/13) 12% (2/16) 14% (2/14) 67% (6/9)
()¼number of patients developing metastasis/total number patients in each group.
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Figure 3 Kaplan–Meier estimates of the probability of metastasis for
A-1012G/Fok 1 combination genotypes.
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smalignancy, it is necessary to employ a sample of patients
which is representative in terms of severity of the disease in
general if, as in this case, the variable is also related to the
outcome. Failure to do this may be a cause of some of the
conflicting results in the literature. The cases were therefore
stratified according to Breslow thickness, which is the best single
predictor of MM outcome.
The promoter polymorphism was clearly related to outcome as
assessed by the development of metastasis (Figure 2, Table 3).
There was a weaker relationship with thicker Breslow thickness
groups. We have previously reported a relationship of Taq 1 and
Fok 1 variant gene combination (ttff) with increased Breslow
thickness (Hutchinson et al, 2000). This was true in the present
study (Po0.005), but the ttff genotype combination was not
significantly associated with metastasis.
The relationship between the A-1012G genotype and develop-
ment of metastasis was also analysed by Cox’s proportional-hazard
regression, correcting for Breslow group, when the promoter
genotype retained significance. The VDR would therefore appear to
be related to both Breslow thickness and development of
metastasis, but the effect on metastasis is at least partially
independent of tumour thickness. This finding has potential
importance in the interpretation of molecular mechanism of
tumour spread. Also, the inclusion of the VDR promoter genotype
when predicting MM outcome with Breslow thickness group
should potentially enhance precision (Table 4). The highest
proportion of metastases occurred in patients who had both AA
genotype and the thickest tumours (Breslow thickness group 4).
However, some thinner tumours developed metastasis, but usually
in the context of AA genotype. Studies on a larger scale are
required to further investigate the predictive capacity of this
polymorphism.
Neither the Fok 1 nor Taq 1 polymorphism was significantly
related to the development of metastasis. However, the promoter
and Fok 1 combination genotype (AAff) was greatly associated
with a higher propensity to metastasis (Table 3). The Fok 1
polymorphism appears to augment the effect of the promoter
polymorphism, as evidenced by a significant statistical interaction
on Cox’s regression and a significant difference in prognosis
associated with AAff compared with AAFf/AAFF genotype
combinations (Table 3), despite no similar difference between ff
and Ff/FF.
The mechanism of action of this promoter polymorphism is not
known. One possibility is that the polymorphism modulates
docking of a transcription factor. The analysis of this region with
the TESS database (Schug and Overton, 1997) demonstrates that
the polymorphism is within the core sequence of a likely GATA-3-
binding site in the A allele, while this binding site is not present in
the G allele. Merika and Orkin, (1993) demonstrated that DNA
strands containing the core sequence AGATAT (the reverse
orientation of the A allele) bound human GATA-3, while zero of
63 sequences shown to bind GATA-3 contained the core sequence
AGACAT (the reverse orientation of the G allele). GATA-3 is an
important transcription factor directing the polarisation of naı ¨ve T
cells to Th-2 cells (Rengarajan et al, 2000). 1a,25-dihydroxyvitamin
D3 has been shown to upregulate GATA-3 gene expression and the
GATA-3 protein promotes polarisation to Th-2 (Boonstra et al,
2001). The present findings would suggest that the GATA-3
response element in the A allele of the VDR promoter may produce
a positive feedback loop and amplify the GATA-3-induced
polarisation. Therefore, this polymorphism may influence immune
response to cancer, particularly in cancers, such as MM, which
show high expression of MAGE antigens. Such tumours are
susceptible to Th-1 responses (Tatsumi et al, 2002). The argument
would be that the A allele is associated with a Th-1 to Th-2 switch,
which reduces the Th-1 cytotoxic response to cancer cells. A
further possibility is that A-1012G is a determinant of whether
transcription is initiated in exon 1a or 1d. Exon 1d contains an
alternative start codon, which can lead to the expression of a
significantly N-terminally extended protein (VDRB1). This is
reported to have greater transactivation potential than the short
protein, translated at the conventional start codon in exon 2
(VDRA) (Gardiner and Eisman, 2003), although this has not been
consistently reported (Sunn et al, 2001). The majority of evidence
is that vitamin D and the VDR have a protective effect in cancer
(Osborne and Hutchinson, 2002). Therefore, if A-1012G were
determining the transcription start site, then the G allele would be
expected to be associated with the VDRB1 protein and the A allele
with the shorter VDRA protein, which would be further altered by
the f allele of the Fok 1 polymorphism. This would be compatible
with the finding of enhanced effect of AAff over AA found in the
present study.
In conclusion, the novel VDR promoter polymorphism,
A-1012G, is related to MM occurrence and outcome as predicted
by Breslow thickness but more particularly with the development
of metastasis. This relationship is considerably stronger than the
relationships of the Taq 1 and Fok 1 polymorphisms and their
genotype combinations. The Fok 1 variant enhanced the effect of
the A-1012G/Fok 1 polymorphism on metastasis. The effect on
metastasis is at least partially independent of tumour thickness
and A-1012G may have predictive potential in addition to Breslow
thickness.
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